Building tomorrow's
breakthroughs
Panacea Venture is a healthcare venture fund with global vision and reach dedicated to transforming lives through promising innovation
About our
investment firm
Spun out from Kleiner Perkins China, the founding partners set up a new platform to leverage the sea change occurring in China, while establishing a global footprint to invest in innovation. To date, Panacea Venture raised three USD funds and an RMB fund from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies.
Portfolio
Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale.
.png)
Our approach
We build and capture value from company formation to expansion stage to public market investing.
35+
19+
Venture Partners
100+
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
Day Zero Diagnostics Announces Completion of $16M Financing Round
DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
Day Zero Diagnostics Announces Completion of $16M Financing Round
DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.